Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View
Zacks Investment Research | Oct 27, 2016 03:44AM ET
Alexion Pharmaceuticals, Inc.’s (NASDAQ:ALXN) third-quarter 2016 earnings (including stock-based compensation expense) of $1.03 cents per share missed the Zacks Consensus Estimate of $1.04.
Revenues, on the other hand, soared 20.1% year over year to $799 million. The impact of currency headwind on the top line was 2.5% ($16 million). The majority of the company’s revenues were generated by Soliris. The figure also surpassed the Zacks Consensus Estimate of $784 million.
Soliris Drives Growth
Soliris sales were up 9.6% to $729 million driven by steady growth in patients in both the indications – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Strensiq and Kanuma contributed $61 million and $9 million, respectively, to quarterly revenues.
Operating expenses (including stock-based compensation expense, and upfront and milestone payments related to license and collaboration deals, and other special items) increased. Research and development (R&D) expenses were up 18.1%, while selling, general and administrative (SG&A) expenses climbed 8.3%.
Guidance
Alexion has revised its guidance for total revenue and adjusted earnings for 2016. The company now expects both revenues and adjusted earnings per share to be at the high end of the previously guided ranges of $3.05–$3.1 billion and $4.50–$4.65, respectively.
On the other hand, the company continues to expect Soliris revenues in the range of $2.83–$2.87 billion. Revenues from the metabolic franchise, comprising Kanuma and Strensiq, are now expected in the range $225–$235 million (previous guidance: $200–$220 million).
The company expects R&D expenses and SG&A expenses to be around $680–$690 million (previous expectation: high end of the $650–$680 million band) and $790–$810 million (prior expectation: high end of the $760–$790 million band), respectively.
Pipeline Update
The company continues to progress with the candidates in its pipeline. Currently, the company is evaluating Soliris in a couple of phase III studies – PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder; and PROTECT, for the treatment of delayed graft function. Results from the PROTECT study are expected in the fourth quarter of 2016.
Moreover, Alexion plans to file regulatory submissions for Soliris for the treatment of refractory generalized myasthenia gravis in both the U.S. and the EU in the first quarter of 2017.
ALEXION PHARMA Price and EPS Surprise
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.